There’s a story written in supermarket receipts. You might not know it’s there; it’s buried in the line-by-line itemisation of your weekly grocery run. But Danish researchers have just uncovered it, and what it shows is rather striking. When people start taking glucagon-like peptide-1 receptor agonists (GLP-1RAs), drugs increasingly prescribed for type 2 diabetes and weight loss, their trolleys change. Not radically. Not overnight. But persistently, measurably, across nearly every category of food they buy.
The evidence comes from an unusual place: 1,177 people willing to share their supermarket receipts. Researchers from Copenhagen University Hospital–Steno Diabetes Center Copenhagen tracked these shoppers for a full year before and after they started GLP-1 treatment, watching as their baskets transformed. What emerges isn’t a story of dramatic abandonment of junk food. It’s subtler than that. It’s a story about appetite itself, and what happens to desire when a drug rewires how your brain interprets hunger.
The Pattern in the Data
When you’re first prescribed a GLP-1RA, something shifts. The patients in this study didn’t suddenly become puritanical shoppers overnight. Instead, the mathematics of their weekly shop changed by millimetres that somehow added up to miles. The energy density of what they purchased fell from 209.4 to 207.3 kilocalories per 100 grammes; a decrease so modest you might not notice it in a single biscuit. Yet across 2.3 million purchases tracked over two years, this quiet recalibration manifested as something unmistakable.
Sugar dropped. From 15.7 grammes per 100 grammes in their pre-treatment baskets to 15.1 grammes after starting the medication. Carbohydrates shrank from 19.8 to 19.3 grammes. Saturated fat ticked downward from 7.3 to 7.2 grammes. Meanwhile, protein climbed: from 6.6 to 6.9 grammes. The comparison group, people matched by age, sex, and income who didn’t start GLP-1s, showed the opposite pattern. They bought progressively more of everything; a bit more sugar, a bit more energy, a bit more carbohydrate. Their shopping baskets drifted in one direction. The GLP-1 cohort drifted in another.
But perhaps the sharpest signal came from the categories themselves. The researchers classified every item according to how processed it was: unprocessed foods like raw vegetables and grains, minimally processed items, and then the spectrum of processed and ultraprocessed goods that dominate supermarket shelves. When people started GLP-1s, their purchases of ultraprocessed foods fell by 1.2 percentage points whilst unprocessed foods rose by 0.9 percentage points. Again, the comparison group moved the opposite direction, edging further into the processed realm.
What These Numbers Mean
What we’re actually witnessing, when you look at these receipts, is an echo of something happening in the brain. GLP-1 agonists work by mimicking a hormone your gut naturally produces when you eat. They slow stomach emptying, which makes you feel fuller longer. They also talk directly to appetite centres in your hypothalamus. The part of your brain that decides whether you’re hungry or not. But the drug does something subtle beyond merely suppressing appetite: it appears to reshape what you want.
This isn’t appetite suppression producing indifference to all food equally. It’s more like your brain is being asked to reconsider its priorities. The drugs seem to make ultra-processed foods, those engineered combinations of sugar, refined carbohydrates, and saturated fat that our brains find almost neurologically irresistible, suddenly less compelling. When you’re not as driven by hedonic hunger, when the urge to seek out the most palatable items starts quieting down, you reach for something different. Not because willpower increased. But because the wanting itself changed.
The study involved 293 people starting GLP-1 treatment, tracked alongside 884 matched controls. They were mostly in their early 50s, roughly half male and half female, all living in Denmark where the researchers could access pharmacy records and link them to nearly a decade of accumulated supermarket receipts. That’s the unusual advantage of this kind of population-level research: you get to watch actual behaviour, not what people say they do or what they think they do, but the genuine choices made at checkout.
The Practical Consequence
What’s worth noting is scale. Yes, each individual nutrient shift is modest. A single person buying slightly less sugar per week is not revolutionary. But when you consider the sheer volume of purchasing happening; nearly 1.2 million transactions after GLP-1 initiation compared to 800,000 before; these individual millimetres become population-level movement. And given that GLP-1 prescriptions are accelerating globally, what happens in one person’s shopping basket starts to look like it might eventually be a signal about public health.
The researchers themselves note the limitations. The people willing to share supermarket receipts might not be representative of everyone taking GLP-1s. The study couldn’t fully account for weight loss itself; some of these dietary shifts might reflect someone genuinely trying to lose weight rather than being purely driven by the drug’s physiological effects. There’s always the question of whether these patterns are purely pharmacological or partly psychological: once people feel their appetite responding to medication, they might consciously choose differently too.
Still, there’s something satisfying about using receipts as a data source. These aren’t self-reported food diaries, prone to the selective memory and social desirability bias that plague nutrition research. These are the actual items people purchased and, presumably, ate. The pattern is clean enough to suggest something real is happening.
What Comes Next
As GLP-1 drugs become increasingly common; prescribed not just for diabetes but for weight management, and now being explored for cardiovascular health and even Alzheimer’s disease; understanding how they reshape eating behaviour matters more. If these medications systematically shift people toward less processed foods, toward more protein and fewer refined carbohydrates, that has implications. It means the drugs might be doing more than just helping people lose weight. They might be resetting what our food-maximising brains actually choose to reach for.
The recipe-and-receipt world of everyday food purchasing is usually invisible to researchers, hidden away in the proprietary databases of supermarket loyalty schemes and the private decisions made in checkout aisles. But when you have access to it, when you can see the collective pattern across nearly 2 million food choices, it tells a story worth hearing. It tells us that hunger, appetite, desire; the forces that drive us toward food; are not fixed. They’re malleable. A drug that taps into the right neurological circuits can nudge a human brain, subtly but persistently, toward different choices. The shopping basket doesn’t lie about what our appetites have become.
Study link: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2844224
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.